Brief: Tscan Therapeutics Presents Phase 1 Umbrella Trial In Progress On Ha-1 (Tsc-100) And Ha-2 (Tsc-101) At The 64Th American Society Of Hematology Annual Meeting 2022
12/12/2022 15:20
Dec 12 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS PRESENTS PHASE 1 UMBRELLA TRIAL IN
PROGRESS
ON HA-1 (TSC-100) AND HA-2 (TSC-101) AT THE 64TH AMERICAN
SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022
Source text for Eikon: ID:nGNXcgVPMV
Further company coverage: TCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing